🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  2. An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants

    Lacuna Pharma Pty Ltd

    Helicobacter pylori infection, GERD

    phase 1 other active

    1 trial

  3. An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes

    Swedish Orphan Biovitrum Pty Ltd

    Nicotine use

    phase 1 other active

    1 trial

  4. Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial

  5. Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

    Takeda

    Metastatic Adenocarcinoma of the Colon or Rectum

    phase 1 mab completed

    1 trial

  6. Arm 1 cemiplimab

    Regeneron UK Limited

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  7. Arsenic trioxide

    Teva Pharma GmbH

    Chronic Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  8. Aspirin

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients

    Formycon AG

    Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection

    phase 1 other active

    1 trial

  10. Autologous Bone Marrow-derived Mononuclear Cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease

    phase 1 mab completed

    1 trial

  11. Autologous mononuclear cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease, SRV Dependent

    phase 1 mab active

    1 trial

  12. Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients

    The George Institute

    Kidney trasplants

    phase 1 other active

    1 trial

  13. Automated Contingency Management (ACM) software

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate-Replacement Therapy

    phase 1 other completed

    1 trial

  14. Azercabtagene zapreleucel (azer-cel)

    TG THERAPEUTICS, INC.

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial

  15. BBO-10203

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  16. BBO-11818

    BridgeBio Oncology Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  17. BBO-8520

    BridgeBio Oncology Therapeutics

    Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  18. BBP-398

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  19. BBP-398 (Formerly known as IACS-15509)

    BridgeBio Oncology Therapeutics

    Tumor, Solid

    phase 1 small molecule terminated

    1 trial

  20. BBP-398 with nivolumab

    BridgeBio Oncology Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  21. BBP-671

    BridgeBio Oncology Therapeutics

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  22. BBP-711

    BridgeBio Oncology Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  23. BCMA/CD19 Dual-Target CAR-T

    Xijing Hospital

    Multiple Myeloma

    phase 1 mab active

    1 trial

  24. BCMA/CD70-targetd CAR-T

    Chongqing Precision Biotech Co., Ltd

    Juvenile Dermatomyositis (JDM)

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources